ENGN
NASDAQ · Biotechnology
Engene Holdings Inc
$1.50
-0.22 (-12.79%)
Open$1.71
Previous Close$1.72
Day High$1.75
Day Low$1.45
52W High$12.25
52W Low$1.70
Volume—
Avg Volume2.89M
Market Cap592.86M
P/E Ratio—
EPS$-2.25
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+4,255.3% upside
Current
$1.50
$1.50
Target
$65.33
$65.33
$48.23
$65.33 avg
$96.03
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 102.93M | 108.44M | 88.87M |
| Net Income | -18,276,199 | -22,730,064 | -15,420,094 |
| Profit Margin | -17.8% | -21.0% | -17.4% |
| EBITDA | -27,166,221 | -28,388,210 | -21,820,067 |
| Free Cash Flow | -19,844,248 | -21,752,544 | -13,746,863 |
| Rev Growth | +6.4% | +6.6% | +8.6% |
| Debt/Equity | 0.41 | 0.31 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |